Switzerland-based Merck Serono, a division of Germany's Merck KGaA, says that a new formulation of its multiple sclerosis drug Rebif (interferon beta-1a) has been made available in the UK. Late last year the BRIGHT trial, published in the journal Multiple Sclerosis, indicated that the product was associated with a greater occurrence of injection reactions than competitor treatments, including Bayer's Betaseron (interferon beta-1b; Marketletter November 12, 2007).
Merck said that data from a recent two-year Phase IIIb study, which enrolled 260 patients suffering from relapsing/remitting forms of the disease, indicated that the new Rebif formulation was associated with a near three-fold reduction in injection site reactions compared with the older version of the drug (30.8% versus 85.8%).
Commenting on the data, Gavin Giovannoni from the Royal London Hospital in the UK, said: "injection site reactions can lead to discontinuation of therapy in some [MS] patients; the notable reduction in these reactions with Rebif New Formulation has positive implications for tolerability and adherence."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze